Stocktoria
Adagene Inc. ADAG
Adagene Inc. (ADAG) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $7.7M at a -229.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.667 |
| Retained earnings / assets | -4.201 |
| EBIT / assets | -0.274 |
| Equity / liabilities | 1.341 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2/9 | 6.19 | — | — |
| ACRS | Aclaris Therapeutics, Inc. | 2/9 | -18.21 | — | -58.2% |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
FAQ
Is ADAG financially healthy?
Adagene Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ADAG pay a dividend?
No, Adagene Inc. does not currently pay a dividend.
How profitable is ADAG?
In FY2025, Adagene Inc. had a net margin of -229.6% and a return on equity of -49.8%.
What is the analyst price target for ADAG?
The average Wall-Street price target for Adagene Inc. is $9.40, about 150.7% above the recent price, from 5 analysts.
Is ADAG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Adagene Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.